Villejuif

• PLGG – MEKTRIC (Pediatric Low Grade Glioma – MEKinhibitor TRIal vs Chemotherapy) Recruiting
  2023-508531-30-00 4 2024-03-25 grade 1 glioma/mixed glio-neuronal tumors or pleomorphic xanthoastrocy
• Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3-DXd m … Recruiting
  2023-505925-15-00 7 2024-03-21 Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-low defined
• A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) … Recruiting
  2023-504323-25-01 5 2024-03-19 breast cancer
• A Master rollover study to provide continued access to, and assess, long term safety of the study drugs. Recruiting
  2023-506330-73-00 5 2024-03-13 Advanced (unresectable or metastatic) human epidermal growth receptor
• CAPSAPED Recruiting
  2022-500265-27-00 5 2024-03-05 Chronic postchirurgical or post-traumatic neuropathic pain
• A Phase 1/2, Open-Label, Randomized, Dose Finding and Dose Expansion Study of Gedatolisib in Combination with Darolutamide in Metastatic Cas … Recruiting
  2023-505898-32-00 9 2024-02-28 Metastasic Castration-Resistant Prostate Cancer (mCRPC)
• A Phase I Study of VVD-133214 Alone and in Combination in Participants with Advanced Solid Tumors Recruiting
  2023-503170-20-01 1 2024-02-26 Advanced solid tumors
• Treatment for breast cancer patients with meninges invaded by tumor cells Recruiting
  2022-502351-60-00 4 2024-02-22 Patients having a HER2-amplified metastatic breast cancer with evoluti
• Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib … Recruiting
  2023-503708-10-00 5 2024-02-20 Locally advanced or metastatic breast cancer
• Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors Recruiting
  2023-506604-18-00 1 2024-02-14 Triple negative breast cancer
• CUSTOMIZED ANTIBIOTIC TREATMENT DURATION AMONG HOSPITALIZED PATIENTS WITH MODERATELY SEVERE COMMUNITY-ACQUIRED PNEUMONIA [CAT-CAP] Recruiting
  2023-504208-27-00 5 2024-02-12 Community-acquired pneumonia
• A study to evaluate the effects and safety of INCA033989 in participants with myelofibrosis or essential thrombocythemia Recruiting
  2022-502514-86-00 1 2024-02-07 Myeloproliferative Neoplasms
• A Phase 1/2 study of Enzomenib (DSP-5336) in Adult Patients with Acute leukemia Recruiting
  2022-502741-10-00 7 2024-01-26 Acute Leukemia with Mixed Lineage Leukemia (MLL)-rearrangement or Nucl
• FIRST IN-HUMAN STUDY EVALUATING THE EFFECT OF VARIOUS DOSES OF ODM-212 IN SUBJECTS WITH SELECTED ADVANCED SOLID TUMOURS Recruiting
  2022-503061-29-00 7 2024-01-22 Neoplasms benign malignant and unspecified (incl cysts and polyps). Me
• A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part … Recruiting
  2022-503092-28-00 5 2024-01-08 Relapsed/Refractory Follicular Lymphoma
• A study of STX-478 alone and in combination with other anticancer drugs in participants with advanced solid tumors. Recruiting
  2023-504807-94-00 7 2023-12-26 Breast Cancer; Advanced solid tumors including but not limited to gyne
• A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic B … Recruiting
  2022-503114-23-00 3 2023-12-19 Breast Cancer
• A Phase 1, Open-Label, Multicenter Study of INCA033890 in Participants with Advanced or Metastatic Solid Tumors Recruiting
  2022-502456-31-00 1 2023-11-30 Advanced or metastatic solid tumors
• Study comparing thymoglobulin to grafalon, two treatments used to prevent graft versus host disease in elderly patients with acute myeloid l … Recruiting
  2023-504555-27-00 5 2023-11-28 Myelodysplastic syndrome (MDS)
• 177Lu-edotreotide compared to everolimus in neuroendocrine tumors of the lung and thymus Recruiting
  2022-502154-13-00 5 2023-10-27 Patients with well to moderately differentiated neuroendocrine tumors
• Phase 1/2 Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis Recruiting
  2022-502597-16-00 9 2023-10-27 Intermediate or High-risk Primary or Secondary Myelofibrosis
• A Phase 1/2 Study of the CTPS1 Inhibitor STP938 in Adult Subjects with Relapsed/Refractory B Cell and T-Cell Lymphomas Recruiting
  2022-502299-21-00 1 2023-10-18 Relapsed/refractory (R/R) B-cell and T-cell lymphomas
• Study evaluating thromboprophylaxis in patients with advanced germ cell tumours of good or intermediate prognosis Recruiting
  2022-502426-41-00 5 2023-10-17 Thromboprophylaxis in good and intermediate prognosis advanced germ ce
• ROSY-T: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Osimertinib (TAGRISSO) and are Judged by the Investig … Recruiting
  2022-501528-58-00 5 2023-10-16 Various tumor types depending on the parent study

Showing 385–408 of 961 trials